Invesco
ORIC icon

Invesco’s Oric Pharmaceuticals ORIC Stock Holding History

Invesco’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Sell
108,954
-788
-0.7% -$8.95K ﹤0.01% 2721
2025
Q4 		$898K Buy
109,742
+18,128
+20% +$209K ﹤0.01% 2958
2025
Q3 		$1.1M Buy
91,614
+30,051
+49% +$316K ﹤0.01% 2884
2025
Q2 		$625K Buy
61,563
+21,144
+52% +$142K ﹤0.01% 3066
2025
Q1 		$226K Buy
40,419
+16,461
+69% +$144K ﹤0.01% 3462
2024
Q4 		$193K Buy
23,958
+1,876
+8% +$17.2K ﹤0.01% 3523
2024
Q3 		$226K Sell
22,082
-538
-2% -$5.32K ﹤0.01% 3489
2024
Q2 		$160K Sell
22,620
-471,548
-95% -$4.22M ﹤0.01% 3680
2024
Q1 		$6.79M Buy
494,168
+124,946
+34% +$1.48M ﹤0.01% 2045
2023
Q4 		$3.4M Buy
369,222
+27,685
+8% +$200K ﹤0.01% 2413
2023
Q3 		$2.07M Sell
341,537
-62,235
-15% -$510K ﹤0.01% 2584
2023
Q2 		$3.13M Buy
+403,772
New +$2.29M ﹤0.01% 2465
2022
Q2 		– Sell
-12,167
Closed -$65K – 4112
2022
Q1 		$65K Buy
12,167
+157
+1% +$1.41K ﹤0.01% 3905
2021
Q4 		$176K Sell
12,010
-1,516
-11% -$23.6K ﹤0.01% 3812
2021
Q3 		$282K Buy
13,526
+1,748
+15% +$35.4K ﹤0.01% 3671
2021
Q2 		$209K Buy
+11,778
New +$258K ﹤0.01% 3773

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Invesco's ORIC Position: Q1 2026 in Review

Invesco reduced its Oric Pharmaceuticals (ORIC) stake by 0.72% in Q1 2026, selling an estimated $8.95K and leaving 108,954 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Invesco first reported a position in ORIC in Q2 2021 and has held it in 16 quarters since. The position peaked at $6.79M in Q1 2024. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Invesco held 108,954 shares of Oric Pharmaceuticals worth $1.38M as of Q1 2026.
  • Invesco sold 788 Oric Pharmaceuticals shares in Q1 2026, an estimated $8.95K.
  • Oric Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2721 holding.
  • Invesco first reported a position in Oric Pharmaceuticals in Q2 2021 and has held it in 16 quarters since.
  • Invesco's Oric Pharmaceuticals position peaked at $6.79M in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.